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Abstract Venous thromboembolism (VTE) is a serious
and often fatal medical condition with an increasing inci-
dence. The treatment of VTE is undergoing tremendous
changes with the introduction of the new direct oral anti-
coagulants and clinicians need to understand new treatment
paradigms. This manuscript, initiated by the Anticoagula-
tion Forum, provides clinical guidance based on existing
guidelines and consensus expert opinion where guidelines
are lacking. In this chapter, we address the management of
patients presenting with venous thrombosis in unusual
sites, such as cerebral vein thrombosis, splanchnic vein
thrombosis, and retinal vein occlusion. These events are
less common than venous thrombosis of the lower limbs or
pulmonary embolism, but are often more challenging, both
for the severity of clinical presentations and outcomes and
for the substantial lack of adequate evidence from clinical
trials. Based on the available data, we suggest anticoagu-
lant treatment for all patients with cerebral vein thrombosis
and splanchnic vein thrombosis. However, in both groups a
non-negligible proportion of patients may present with
concomitant bleeding at the time of diagnosis. This should
not contraindicate immediate anticoagulation in patients
with cerebral vein thrombosis, whereas for patients with
splanchnic vein thrombosis anticoagulant treatment should
be considered only after the bleeding source has been
successfully treated and after a careful assessment of the
risk of recurrence. Finally, there is no sufficient evidence to
support the routine use of antithrombotic drugs in patients
with retinal vein occlusion. Future studies need to assess
the safety and efficacy of the direct oral anticoagulants in
these settings.
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Introduction
Venous thromboembolism (VTE) can potentially occur in
any section of the venous system. Although the most
common clinical presentations involve the deep veins of
the lower limbs and the pulmonary arteries, VTE is also
diagnosed in the cerebral venous system, in the abdominal
and pelvic veins, or in the retinal veins, among other sites.
The occurrence of VTE in unusual sites represents a clin-
ical challenge because of the potential severity of clinical
outcomes and because treatment strategies are not sup-
ported by adequate evidence from clinical trials. In this
guidance document, we will review available evidence on
the management of cerebral vein thrombosis, splanchnic
vein thrombosis, and retinal vein occlusion.
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Cerebral vein thrombosis (CVT) most commonly affects
young adults, with 75 % of events occurring in women, and
has a wide spectrum of signs and symptoms, which may
evolve suddenly or over the weeks [1]. Headache is the
most frequent presenting symptom. Other clinical presen-
tations include seizures, focal neurological deficits, altered
consciousness, and papilledema, which can present in
isolation or in association with other symptoms [2]. Risk
factors associated with CVT include gender-related sys-
temic prothrombotic factors such as the use of oral con-
traceptives or pregnancy and local risk factors such as head
injury, neurological procedures, lumbar puncture, and
infections, in particular otitis and mastoiditis, and menin-
gitis [1].
The clinical outcome of CVT appears to be more
favourable than with thrombosis of the cerebral arteries.
Still, in a systematic review of the literature the estimated
mortality rate was 5.6 % (range 0–15.2 %) during the
acute phase of the disease and 9.4 % (0–39 %) after a
follow up that ranged across studies from 6 months to
10.2 years [3]. Residual disability was detected in about
10.0 % of the patients after follow up [3]. Finally, the
estimated annual incidence of recurrent venous throm-
bosis was reported to range between 2.0 and 2.4/100
patient years [4, 5].
Splanchnic vein thrombosis
Splanchnic vein thrombosis (SVT) encompasses Budd–
Chiari syndrome, portal vein thrombosis, mesenteric vein
thrombosis, and splenic vein thrombosis. Of all symptoms,
abdominal pain is the most frequent. Other clinical mani-
festations may be associated with the underlying disorder
and/or may represent the consequence of the acute
thrombosis, such as in the case of gastrointestinal bleeding
and ascites [6]. Systemic risk factors such as hematologic
disorders, autoimmune diseases and the use of hormonal
therapy are the most common risk factors associated with
Budd–Chiari syndrome, whereas local precipitating factors
such as solid abdominal cancer, liver cirrhosis, intraab-
dominal inflammatory conditions, and surgery are the most
common risk factors associated portal and mesenteric vein
thrombosis [6]. Thus, a careful imaging of the abdominal
organs often identifies underlying predisposing pathologies
in these patients. Myeloproliferative neoplasms have
emerged as a leading systemic cause of SVT, and screening
for the JAK2V617F mutation should be considered in
patients without a known major underlying provocative
factor [7].
Overall survival after long-term follow up is lower than
in patients with deep vein thrombosis of the lower limbs,
and depends on the location of thrombosis and on under-
lying diseases [6]. Long-term sequelae include, among
others, portal hypertension and liver cirrhosis [8]. Bleeding
is commonly reported during follow up, and may be related
to underlying diseases, esophageal varices and anticoagu-
lant treatment [6, 9, 10]. The annual incidence of recurrent
thrombosis was reported to be about 2.5/100 patient years
[9, 11].
Retinal vein occlusion
Retinal vein occlusion (RVO) is the second most common
retinal vascular disease after diabetic retinopathy. It may
affect the central retinal vein or its branches, and the most
common clinical presentation is sudden, unilateral and
painless loss of vision, generally caused by macular edema
[12]. Branch RVO may present with peripheral visual-field
defect only or may be asymptomatic [12]. Both central and
branch RVO can present with or without signs of ischemic
lesions. Similarly to CVT and SVT, predisposing factors
can be local or systemic. Local risk factors include open-
angle glaucoma and inflammatory conditions, while car-
diovascular risk factors such as hypertension, diabetes, and
hyperlipidemia are the most common systemic risk factors
associated with RVO [13]. However, the mechanism of
action of these systemic predisposing factors may relate to
damage of the adjacent artery.
Visual prognosis is related to initial visual acuity, and it
is better for branch RVO than for central RVO, and for
non-ischemic RVO than for ischemic RVO [14, 15]. In
addition to permanent visual loss, other late complications
include vitreous haemorrhages, retinal detachment or
neovascular glaucoma [13]. The risk of recurrence is not
negligible and recurrence may occur in the same eye or in
the fellow eye [16].
Given the lack of high-quality evidence in this area, the
anticoagulation Forum has developed the current document
in order to suggest options for clinicians managing patients
with venous thromboembolism in unusual sites. The issues
addressed throughout include: indication for anticoagula-
tion, selection of antithrombotic agents, contraindications
to treatment, role of thrombolysis.
Methods
To provide guidance on the therapeutic management of
unusual site venous thrombosis, we first developed a
number of pivotal practical questions for each site of
thrombosis considered in this document (Table 1). Ques-
tions were developed by consensus from the authors.
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To address these questions, a literature search of MED-
LINE and EMBASE from January 2004 to August 2014 was
conducted. The following search terms were used and
combined: anticoagulant treatment, anticoagulant therapy,
antithrombotic treatment, heparin, low molecular weight
heparin, enoxaparin, nadroparin, dalteparin, certoparin,
bemiparin, tinzaparin, parnaparin, reviparin, vitamin K
antagonists, warfarin, acenocoumarol, phenprocoumon,
thrombolysis, thrombolytic treatment, fibrinolytic agent,
fibrinolysis, urokinase, tenecteplase, alteplase, rtPA, tPA;
aspirin, ticlopidine, clopidogrel; cerebral vein thrombosis,
cerebral venous thrombosis, cerebral veins, sinus thrombosis
intracranial; splanchnic vein thrombosis, splanchnic venous
thrombosis, splanchnic veins, portal vein thrombosis,
mesenteric vein thrombosis, splenic vein thrombosis, hepatic
vein thrombosis, Budd–Chiari syndrome; retinal vein
occlusion, retinal vein thrombosis. The search strategy was
restricted to papers published in English. Detailed informa-
tion on the results of the literature search are available upon
request.
For papers published before 2004, we only considered
the most important studies that were likely to influence our
responses to the questions. These studies were selected and
suggested by the authors of this guidance document.
Because we anticipated that in this setting very few
randomized controlled (RCT) trials would have been
available, our selection was not restricted to a specific
study design, but included RCTs, prospective and retro-
spective cohort studies, and case series describing a mini-
mum of ten cases.
Guidance
Cerebral vein thrombosis
(1) Should anticoagulant drugs in patients with CVT be
considered?
Two RCTs and one meta-analysis have compared UFH
and LMWH (nadroparin) with placebo in the acute treat-
ment of CVT [17–19]. The meta-analysis of the two clin-
ical trials found a reduction in death or dependency with
the use of UFH or LMWH [relative risk (RR) 0.33; 95 %
CI 0.08–1.21 for death and 0.46; 95 % CI 0.16–1.31 for
dependency], but this was not statistically significant,
likely because of the very small number of patients
enrolled in the studies (79 patients). There were two epi-
sodes of pulmonary embolism (one was fatal) in the
Table 1 Guidance questions to be considered
Cerebral vein thrombosis
(1) Should anticoagulant drugs in patients with CVT be considered?
(2) Is concomitant bleeding a contraindication to the use of anticoagulant treatment?
(3) Are low molecular weight heparin (LMWH) and unfractionated heparin (UFH) similarly effective and safe for the acute phase treatment?
(4) Is the standard treatment regimen used for patients with deep vein thrombosis of the lower limbs (i.e. heparins for approximately 5–7 days
and warfarin possibly started on the first treatment day) applicable to all patients?
(5) Is there a role for thrombolysis?
(6) What is the optimal duration of anticoagulant therapy after a first episode of CVT?
(7) Is there a role for the direct oral anticoagulants?
Splanchnic vein thrombosis
(1) Should all patients with SVT receive anticoagulant treatment?
(2) Is gastrointestinal bleeding at the time of diagnosis a contraindication to anticoagulant therapy?
(3) Is the standard treatment regimen used for patients with deep vein thrombosis of the lower limbs (i.e. heparins for approximately 5–7 days
and warfarin possibly started on the first treatment day) applicable to all treatable patients?
(4) What factors should be considered before starting anticoagulant treatment in a patient with liver cirrhosis?
(5) Is there a role for thrombolysis?
(6) What are the factors driving treatment duration?
(7) Is there a role for the direct oral anticoagulants?
Retinal vein occlusion
(1) Should antithrombotic drugs in patients with newly diagnosed RVO be considered?
(2) Which antithrombotic treatment should be preferred?
(3) Is there a role for thrombolysis?
(4) How long should antithrombotic drugs be administered in RVO patients?
(5) Is there a rationale for prescribing long-term aspirin treatment?
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placebo group. The use of anticoagulant treatment was not
associated with an increased risk of symptomatic
intracranial haemorrhage. The latest American Heart
Association/American Stroke Association, European Fed-
eration of Neurological Societies, and American College of
Chest Physicians guidelines recommend that anticoagula-
tion should be given to all patients with CVT who do not
have contraindications [20–22].
(2) Is concomitant bleeding a contraindication to the use
of anticoagulant treatment?
Concomitant intracerebral bleeding is not uncommon at
the time of CVT diagnosis [1] and is mainly related to
increased intracranial pressure secondary to thrombosis. The
safety of anticoagulant therapy in patients with concomitant
intracranial bleeding has never been specifically assessed in
clinical studies, but available data suggest that intracerebral
bleeding should not represent a contraindication to antico-
agulation. Specifically, Einhaupl et al. [17] reported that
three patients with previous intracerebral haemorrhage
recovered completely and had no recurrent haemorrhages in
the UFH group, and DeBruijn et al. [18] reported no
recurrent intracerebral haemorrhages or clinical worsening
in the 15 patients who presented with intracranial bleeding
in the LMWH group. In the ISCVT prospective cohort
study, about 40 % of patients treated with LMWH or UFH
had intracranial haemorrhage at presentation [23].
Guidance Statement Concomitant intracerebral bleed-
ing at the time of CVT diagnosis should not contraindicate
the use of anticoagulant treatment. Anticoagulants with a
shorter half-life (UFH or LMWH) should be administered
over the first days of therapy and the introduction of oral
anticoagulants should be postponed until the patient is
clinically stable and the neuro-radiological picture
improves.
(3) Are low molecular weight heparin (LMWH) and
unfractionated heparin (UFH) similarly effective and
safe for the acute phase treatment?
No direct comparisons between UFH and LMWH are
available, but data from an indirect comparison based on the
results of the ISCVT study suggest that LMWH may be
more effective and safer than UFH [23]. In particular,
patients treated with LMWH in this prospective cohort study
were more likely to be functionally independent after
6 months after adjustment for prognostic factors and
imbalances and less likely to have new intracerebral
haemorrhages, whereas no difference in mortality rates was
observed [23]. Of patients with intracranial haemorrhage at
baseline, 12 % experienced a new bleeding during follow up
in the group treated with LMWH and 28 % in the group
treated with UFH [23]. The European Federation of
Neurological Societies guideline recommends LMWH over
UFH because of the practical advantages and also based
upon the results of RCTs carried out in patients with deep
vein thrombosis of the lower limbs [20]. However, in a
recent international survey on treatment strategies for CVT
patients, 64 % of physicians reported using UFH and 36 %
LMWH [24]. The advantages of UFH include its shorter
half-life and its potential reversibility, which become crucial
for the treatment of clinically unstable patients or for those
requiring invasive procedures such as lumbar punctures or
decompressive hemicraniectomy [25, 26]. If LMWH is used,
a twice daily regimen may be preferred over a once daily
regimen because of the lower peaks and higher troughs
associated with the twice daily administration.
Guidance Statement LMWH and UFH appear to be
similarly effective and safe for the acute phase treatment.
The use of LMWH may be preferred over UFH for the
majority of patients due to the practical advantages. The
short half-life of UFH may be preferred over LMWH for
clinically unstable patients or for patients requiring inva-
sive procedures.
(4) Is the standard treatment regimen used for patients
with deep vein thrombosis of the lower limbs (i.e.
heparins for approximately 5–7 days and warfarin
possibly started on the first treatment day) applicable
to all patients?
No clinical studies have compared different durations of
parenteral treatment in patients with CVT. However, it
would be reasonable to delay oral anticoagulant initiation
because of the potential need for invasive procedures, the
possible us of thrombolysis in case of clinical worsening,
or the potential risk of new intracranial bleeding over the
first days of therapy [27].
Guidance Statement The introduction of oral antico-
agulants should be considered when the patient is clini-
cally stable; that is, in the presence of normalized level of
consciousness or a remission of mental confusion,
improvement in headache and focal neurological deficits
and improvement in the neuro-radiological picture.
(5) Is there a role for thrombolysis?
One Cochrane review and three systematic reviews
assessed the role of thrombolytic drugs in the acute treat-
ment of CVT [28–31]. There are no RCTs that have
evaluated thrombolytic therapy in this setting, and the
results of the available studies, when combined, suggest a
non-negligible risk of bleeding complications while the
efficacy of the treatment is not assessable.
The European Federation of Neurological Societies
guidelines suggest thrombolysis for patients whose condi-
tions deteriorate despite adequate anticoagulant therapy
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and in whom other causes of deterioration have been ruled
out, possibly in the absence of large intracranial haemor-
rhages and threatening herniation [20]. Intra-vascular
thrombolysis may be preferred if adequate expertise is
available, but no data on direct comparison with systemic
thrombolysis exist.
Guidance Statement The use of either systemic or local
thrombolytic therapy should be restricted to very selected
high-risk patients only, such as in patients who deteriorate
despite adequate anticoagulant therapy in whom other
causes of deterioration have been ruled-out.
(6) What is the optimal duration of anticoagulant ther-
apy after a first episode of CVT and what are the
main factors driving treatment duration?
No clinical studies have specifically addressed the issue
of the optimal duration of secondary prevention of venous
thromboembolism with anticoagulant therapies in patients
with CVT. The results of a systematic review of the liter-
ature report a recurrence rate of 2.8 % after pooling the
results of 13 studies with follow-up duration ranging
between 12 and 145 months [3]. In addition, the rate of
VTE occurring in other sites (apart from CVT) was 3.7 %
[3]. Two more recent studies reported an annual recurrence
rate of any VTE of 2.0 % [4] and of 3.5 % [5], respec-
tively, after discontinuation of anticoagulant treatment and
a median follow up of 6 years and 40 months, respectively.
Male sex and severe thrombophilia were independently
associated with the risk of recurrence in the first study [4];
previous VTE was the only independent predictor of
recurrence in the second study [5]. In the ISCVT study,
male gender and polycythemia or thrombocythemia were
independently associated with the risk of recurrence [32].
This study had a shorter median follow up of 13 months.
The European Federation of Neurology Societies
guidelines suggest 3 months of anticoagulant treatment
when CVT is secondary to a transient risk factor,
6–12 months when CVT is unprovoked and in the presence
of mild thrombophilia, and indefinite treatment duration
when CVT is recurrent or associated with severe throm-
bophilia [20].
Guidance Statement Anticoagulant treatment for a
minimum of 3 months should be considered in patients with
transient risk factors. Patients without known risk factors
should be considered for 6–12 months of anticoagulation.
It appears safe to discontinue anticoagulant treatment in
the presence of transient risk factors such as oral contra-
ceptive use, while indefinite treatment duration should be
considered for patients with recurrent CVT and in patients
with permanent major risk factors including severe
thrombophilia (antithrombin, protein C or protein S defi-
ciency; antiphospholipid antibodies syndrome; homozygous
factor V Leiden or prothrombin gene mutation or combined
heterozygous mutation).
(7) Is there a role for the direct oral anticoagulants?
No CVT patients have been enrolled in phase III clinical
trials of the direct oral anticoagulants. We found only one
report of seven patients with CVT treated with rivaroxaban
[33]. In this report, no major bleeding events were docu-
mented and the overall outcome was reported to be
favourable. Given the results of the RCTs comparing the
direct oral anticoagulants with standard treatment in
patients with deep vein thrombosis and/or pulmonary
embolism and given the fast onset and offset of action of
these compounds, it seems plausible that the direct oral
anticoagulants will have a role also in this setting. How-
ever, additional evidence is needed before recommending
for or against their use in this setting.
Guidance Statement Given the absence of clinical
experience with the use of the direct oral anticoagulants in
this setting, there is no evidence for or against their use in
clinical practice until additional data from clinical studies
will become available. If a decision to use these agents is
made, their use should be considered off-label and careful
patient counselling and clinical monitoring should follow.
Ideally, patients receiving direct oral anticoagulants
should be included in prospective cohort studies aimed to
fill this knowledge gap.
Splanchnic vein thrombosis
(1) Should all patients with SVT receive anticoagulant
treatment?
We found no RCTs assessing anticoagulant treatment in
this setting and available evidence is based on the results of
observational studies. The results of these studies suggest
that the use of anticoagulants is associated with improved
survival [6], with a lower risk of recurrence [9, 10, 34], and
with improved recanalization [33, 34], but also with an
increased risk of gastrointestinal bleeding [6].
An increasing number of SVTs are diagnosed inciden-
tally in asymptomatic patients. Whether these events are
associated with a lower risk of recurrence as compared to
symptomatic events, and whether anticoagulation is
effective in these patients is unknown. It should be noted
that the majority of patients with incidentally detected SVT
have major permanent risk factors such as cancer or liver
cirrhosis [35, 36].
The American College of Chest Physicians guidelines
recommend anticoagulation for symptomatic SVT patients,
and no anticoagulation for asymptomatic patients with
incidentally detected events [37]. Anticoagulation for
patients with acute and chronic portal vein thrombosis and
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Budd Chiari syndrome is recommended by the American
Association for the Study of Liver Diseases [38].
However, patients with SVT may present with active
gastrointestinal bleeding or with a very high risk of
bleeding due to concomitant underlying disorders. In these
patients, the risks associated with anticoagulation may
offset its benefits. In a prospective study aimed at
describing treatment strategies for SVT patients in real life,
more than 20 % of patients did not receive anticoagulant
treatment [39]. Factors associated with no treatment
included gastrointestinal bleeding at presentation, throm-
bocytopenia, cancer, hepatic cirrhosis, and incidental
diagnosis of SVT [39].
Guidance Statement Anticoagulant treatment should be
considered for all patients with symptomatic SVT and no
evidence of active bleeding. The decision to administer
anticoagulants to patients with incidentally detected,
asymptomatic SVT should be made on an individual basis,
carefully balancing the presence of risk factors for recur-
rence (e.g. underlying prothrombotic conditions) and the
risk of bleeding.
(2) Is gastrointestinal bleeding at the time of diagnosis a
contraindication to anticoagulant therapy?
Gastrointestinal bleeding may be present at the time of
SVT diagnosis in up to 25 % of patients [8]. It is in most
cases associated with esophageal varices, but it can also
occur after intestinal infarction in patients with mesenteric
vein thrombosis. Active gastrointestinal bleeding repre-
sents a contraindication to anticoagulant treatment, but
anticoagulation should be considered in patients with pre-
vious bleeding, in particular when at high risk of thrombus
extension or recurrence. However, the optimal timing for
starting anticoagulant therapy is unknown and it should be
decided on an individual basis taking into account the
management of bleeding sources and the presence of
additional risk factors for bleeding. For example, in some
cases, it may make sense to start anticoagulation only after
the high pressure due to venous obstruction has been
relieved.
Guidance Statement In the presence of active bleeding,
anticoagulant treatment should be initiated only when the
bleeding source has been successfully treated and the
patient is clinically stable. The decision to start anticoag-
ulant treatment should be driven by the presence of major
risk factors for recurrence, the ability to address the
underlying cause for bleeding, and by the location and
extent of thrombosis.
(3) Is the standard treatment regimen used for patients
with deep vein thrombosis of the lower limbs (i.e.
heparins for approximately 5–7 days and warfarin
possibly started on the first treatment day) applicable
to all treatable patients?
SVT is associated with solid cancer in approximately
22–27 % of patients [6, 39]. LMWH has been shown to be
more effective than warfarin in patients with cancer-asso-
ciated deep vein thrombosis of the lower limbs or pul-
monary embolism and, for this reason, LWMH is the
current treatment of choice at least for the first 3–6 months
in this population [37]. Although no studies comparing
LMWH with warfarin are available in SVT patients, it is
plausible that the clinical benefit of LMWH is similar also
in this setting
The initiation of warfarin on the first days of treatment
may not be practical or safe in high bleeding risk patients
such as patients with known esophageal varices or throm-
bocytopenia, or in unstable patients who may be requiring
invasive procedures such as portosystemic shunting. In these
patients, treatment with LMWH alone (or with UFH in some
circumstances) should be preferred, due to its shorter half-
life. Dose reductions of LMWH should be considered in
patients with thrombocytopenia, although there is no ade-
quate evidence to support any specific dosing algorithm
based on platelet count. Some experts suggest to use a half
therapeutic dose (i.e. 100 IU/kg daily) in patients with a
platelet count between 50,000 and 100,000 mm3, and a
prophylactic dose in patients with a platelet count between
30,000 and 50,000 mm3, and no anticoagulation below
30,000 mm3. Other experts suggest the dose be reduced only
when the platelet count is below 50,000 mm3 in patients
without concomitant major risk factors for bleeding (e.g.
esophageal varices). For patients with hepatic injury, pro-
longed hospitalization with poor nutrition, or antibiotic
therapy, initially warfarin dosing should be judicious so as
not to overshoot the INR target [2.0–3.0].
Guidance Statement This treatment regimen may not be
appropriate for patients with cancer-associated SVT or for
patients with major risk factors for bleeding (e.g. liver cir-
rhosis and/or known esophageal varices, thrombocytope-
nia), for whom an initial course of treatment with LMWH
(3–6 months for cancer patients) is preferable. In patients
with thrombocytopenia, reduced doses of LMWH should be
used (prophylactic or half therapeutic dose) according to the
platelet count and to the concomitant presence of additional
risk factors for bleeding. For all other patients, the intro-
duction of warfarin should be considered only when the
patient is clinically stable. In patients at very high risk of
bleeding or possibly requiring invasive procedures the use
of UFH may be preferred over LMWH.
(4) What factors should be considered before starting
anticoagulant treatment in a patient with liver
cirrhosis?
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Approximately 24–28 % of SVT patients have known
liver cirrhosis [6, 39]. In these patients, bleeding risk
associated with the presence of portal hypertension needs
to be carefully assessed. Esophageal varices have been
consistently reported to be associated with an increased
risk of bleeding in SVT patients [6, 9], but their presence
does not represent an absolute contraindication to antico-
agulant therapy, because treatment of SVT may improve
the portal hypertension. However, before starting antico-
agulants, routine endoscopic screening of esophageal
varices and prophylactic treatment of variceal bleeding, if
indicated, may be warranted. In a management study by
Senzolo et al., 35 patients with portal vein thrombosis and
cirrhosis underwent endoscopic screening of esophageal
varices, and patients with previous variceal bleeding and
those with grade II esophageal varices with red signs and
grade III varices were banded [40]. Anticoagulation with
LMWH was started not earlier than 15 days after the last
banding session. One episode of variceal bleeding was
reported in this study. In another study, 55 cirrhotic
patients with portal vein thrombosis were treated with
either warfarin or LMWH and the main study outcome was
the rate of complete recanalization of the portal vein [41].
Of interest, initiation of anticoagulant treatment within the
first 2 weeks after diagnosis was the only predictive factor
for complete recanalization. The majority of these patients
(78 %) received beta-blockers for prophylaxis of variceal
bleeding.
Guidance Statement Routine endoscopic screening of
esophageal varices and prophylactic treatment of variceal
bleeding should be considered for all cirrhotic patients
with SVT. In patients who are not actively bleeding, anti-
coagulant treatment should be started as soon as possible
with initially reduced doses of LMWH (either prophylactic
doses or half therapeutic doses also according to the pla-
telet count). Full doses of LMWH should be started only
after the completion of the banding treatment.
(5) Is there a role for thrombolysis?
Case reports describe the use of thrombolytic therapy in
SVT patients [42–47]. Different strategies were used,
including systemic intravenous administration or catheteri-
zation of the superior mesenteric artery or the portal vein. In
some of these cases this approach was reported to be ben-
eficial, but others reported a high risk of major or even fatal
bleeding [47]. For this reason, the use of thrombolytic agents
should be limited to very selected cases, such as mesenteric
vein thrombosis patients with signs of intestinal ischemia or
patients whose conditions deteriorate despite adequate
anticoagulant therapy. There are insufficient data to suggest
a preference for local or systemic lysis, and the choice
should be based on local experience and preferences.
Guidance Statement The use of thrombolytic agents
should be limited to very selected cases, such as patients
with mesenteric vein thrombosis and with signs of intestinal
ischemia or patients whose conditions deteriorate despite
adequate anticoagulant therapy.
(6) What is the optimal duration of anticoagulant ther-
apy after a first episode of SVT and what are the
factors driving treatment duration?
In a large retrospective cohort of 832 patients with
portal, mesenteric, splenic, and hepatic vein thrombosis,
the annual incidence of recurrent VTE after a mean follow-
up of 27 months was 3.5 per 100 patient-years [6]. In this
study, only 28 % of patients received warfarin, which in
75 % of cases was prescribed for an indefinite period of
time. Hormonal therapy was the only independent risk
factor for recurrence, while the use of warfarin was not
protective. In a retrospective study enrolling 136 non-cir-
rhotic patients with portal vein thrombosis only, the inci-
dence rate of thrombotic events after a median follow-up of
46 months was 5.5 per 100 patient-years [9]. Fifty-two
patients were not treated with anticoagulants, 30 were
treated for a definite period of time (mean treatment
duration not reported), and 54 remained on anticoagulant
treatment during the whole study period. The presence of
an underlying prothrombotic state was independently
associated with the risk of recurrence, while the use of
anticoagulant therapy was associated with a statistically
significant reduction in recurrent events. In the retrospec-
tive cohort study by Spaander et al., 66 of 120 non-cirrhotic
patients with portal vein thrombosis received anticoagulant
treatment, and the overall thrombotic risk at 1, 5 and
10 years was 4, 8, and 27 %, respectively [10]. The use of
anticoagulant therapy was associated with a lower risk of
recurrence, but also with a significant increase in bleeding
risk. Recurrent thrombosis, but not bleeding, was associ-
ated with poor survival. Finally, the annual risk of recur-
rence in 77 patients with mesenteric vein thrombosis all
treated with vitamin K antagonists was found to be 4.6 %
person-years in the about 40 % of patients who discon-
tinued anticoagulant treatment [11].
The American Association for the Study of Liver Dis-
eases recommends anticoagulant therapy for at least
3 months for all patients with acute portal vein thrombosis,
and long-term anticoagulation for patients with concomi-
tant mesenteric vein thrombosis or patients with permanent
thrombotic risk factors [38]. The majority of SVT patients
have underlying prothrombotic risk factors, which in most
cases are permanent. Recurrent thrombosis may be severe
since in about one fourth of cases it occurs as hepatic,
mesenteric, or splenic infarctions [9]. Anticoagulant treat-
ment is effective in preventing recurrence, but bleeding
rates reported in SVT patients appear to be higher than
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those reported in patients with deep vein thrombosis of the
lower limbs. However, in the study on patients with MVT
only, case-fatality rate of thrombosis was significantly
higher than that of gastrointestinal bleeding [11]. Whether
patients with SVT plus a symptomatic myeloproliferative
syndrome with positive JAK2 V617F mutation can safely
transition from anticoagulation to aspirin therapy once they
have started cytoreductive therapy or JAK2 inhibitors (e.g.
with hydroxyurea or interferon) is not known.
Guidance Statement Anticoagulant treatment should be
administered for a minimum of 3 months to all SVT
patients. It appears safe to discontinue anticoagulant
treatment in the presence of major transient risk factors,
such as surgery or infections. For all other patients,
including patients with cirrhosis, cancer including myelo-
proliferative neoplasms, or autoimmune disorders, indefi-
nite treatment duration should be considered with periodic
careful assessment of the risks and benefits.
(7) Is there a role for the direct oral anticoagulants?
No SVT patients have been enrolled in phase III clinical
trials of the direct oral anticoagulants. We found only two
published case reports of PVT or MVT patients treated
with rivaroxaban [48, 49]. Although direct oral anticoag-
ulants represent important alternatives to LMWH and
warfarin also in this setting, the reported increased risk of
gastrointestinal bleeding in phase III clinical trials, at least
with some molecules, remains a matter of concern. Fur-
thermore, the direct oral anticoagulants are contraindicated
in patients with acute or chronic severe liver impairment as
a result of their partial metabolism through the CYP 3A4
system [50]. Thus, additional evidence is needed; pending
such evidence, we can neither recommend for or against
the use of direct oral anticoagulants in the management of
SVT patients.
Guidance Statement Given the absence of clinical
experience with the use of the direct oral anticoagulants in
this setting, there is no evidence for or against their use in
the management of patients with SVT. If a decision to use
these agents is made, their use should be considered off-
label and careful patient counselling and clinical moni-
toring should follow. Ideally, patients receiving direct oral
anticoagulants should be included in prospective cohort
studies aimed to fill this knowledge gap.
Retinal vein occlusion
(1) Should antithrombotic drugs in patients with newly
diagnosed RVO be considered?
A systematic review of the literature identified only one
RCT comparing an antithrombotic drug with placebo in 89
patients [51, 52]. In this study, the use of ticlopidine
administered for 6 months was associated with a trend
toward improved visual acuity [52]. Since then, no other
studies have used placebo as a comparator. In a prospective
cohort study of 686 RVO patients, patients treated with
aspirin had a worse visual outcome than patients who did
not receive aspirin [53]. The guidelines of the Royal Col-
lege of Ophthalmologists recommend against the use of
antithrombotic drugs for patients with RVO [54]. However,
because of the thrombotic nature of the occlusion and
because of the association between RVO and cardiovas-
cular risk factors, aspirin is commonly prescribed to RVO
patients, at least in some institutions [53, 55].
Guidance Statement There is no high-quality evidence
to support routine use of antithrombotic drugs for RVO
patients. Neither the benefits nor the risks of antithrombotic
therapy have been well defined in this clinical setting. That
notwithstanding, antithrombotic treatment may be consid-
ered in selected patients with recent onset of symptoms and
no local risk factors for thrombosis (e.g. glaucoma) or in
patients with underlying major prothrombotic risk factors
such as the antiphospholipid antibodies syndrome.
(2) Which antithrombotic treatment should be
preferred?
Three small RCTs have compared the efficacy and
safety of LMWH and aspirin for the treatment of patients
with RVO [56–58]. A meta-analysis of these studies found
a statistically significant improvement in visual acuity and
a 78 % risk reduction in adverse ocular outcomes with the
use of LMWH, with no increased risk of vitreous haem-
orrhage [59]. In these studies, treatment was started within
15 [56] or 30 days [57, 58] after the onset of symptoms and
was continued for 20–30 days [57, 58] or 3 months [56].
The use of anticoagulants during the acute phase of disease
remains controversial and largely varies among different
institutions. Some experts support the use of anticoagula-
tion in patients with concomitant severe thrombophilia,
such as the antiphospholipid antibody syndrome.
Guidance Statement If antithrombotic therapy is used,
LMWH administered at therapeutic doses may be consid-
ered for the acute phase treatment of RVO.
(3) Is there a role for thrombolysis?
Two RCTs have compared fibrinolytic therapy with no
treatment [60] or hemodilution [61]. In the first study
patients received intravenous streptokinase for 72 h fol-
lowed by UFH and then warfarin for 6 months [60].
Treatment was started within 7 days from symptoms onset.
In the second study, patients received intravenous rt-PA for
60 min, UFH for 8 days and aspirin for 12 weeks and
treatment was started within 11 days from symptoms onset
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[61]. There was a trend toward improved visual acuity in
the groups of patients receiving active treatments, with
similar rates of vitreous haemorrhage.
Guidance Statement The use of locally administered
thrombolytic therapy should be limited to very selected
cases, such as RVO patients with total visual loss.
(4) How long should antithrombotic drugs be adminis-
tered in RVO patients?
Few studies reported on the long-term incidence of RVO
recurrence. One study reported an annual incidence of
ipsilateral RVO recurrence of about 1 % [62], in another
study the incidence of recurrence in the same eye was
0.9 % after 2 years and 2.5 % after 4 years [63]. In this
latter study that enrolled 1,108 patients, the cumulative
probability of recurrence in the fellow eye was 7.7 % after
2 years and 11.9 % after 4 years [63]. Pooling the results
of 24 studies on patients with branch RVO and 53 studies
with central RVO, a systematic review of the literature
reported that 5 % of patients with central RVO developed a
recurrent RVO over a 1-year period [16]. The role for
antithrombotic agents in the long-term secondary preven-
tion of RVO remains unexplored and there are no available
data to suggest that antithrombotic treatment reduces the
risk of recurrence. Treatment duration in RCTs ranged
from few weeks to 6 months.
Guidance Statement If antithrombotic therapy is used,
LMWH should be administered for a period of 1–3 months.
Aspirin should be administered for an indefinite period of
time, when indicated.
(5) Is there a rationale for prescribing long-term aspirin
treatment?
A number of studies have reported an association
between RVO and hypertension or diabetes [64–67]. Other
studies have reported higher mortality rates from cardio-
vascular disease in patients with RVO than in patients with
no RVO [68, 69]. Combining the populations of two large
prospective cohort studies with a total of 8,384 individuals,
Cugati et al. reported that subjects aged less than 70 years
with RVO had a significantly higher risk of cardiovascular
mortality than patients without RVO (HR 2.5, 95 % CI
1.2–5.2) [69]. This increased risk was not observed in older
patients after adjusting for cardiovascular risk factors.
Finally, in a systematic review and meta-analysis, Khan
and colleagues have recently assessed the 10-year Fram-
ingham risk for patients with RVO [70]. The estimated
10-year Framingham risk score in subjects with RVO was
10.1 % (95 % CI 9.9–10.2), and it was significantly higher
than the average risk score of 6 % calculated in the general
population.
Whether RVO may occur as the first clinical manifes-
tation of arteriosclerosis in some patients, and whether
long-term treatment with aspirin may effectively prevent
cardiovascular morbidity and mortality in these patients is
unknown.
Guidance Statement The decision to prescribe long-
term aspirin treatment should be based on an individual
patient assessment and should also take into account other
concomitant indications for the primary or secondary
prevention of cardiovascular disease.
Conclusion
The treatment of venous thrombosis occurring in unusual
sites is particularly challenging because of the lack of
evidence from clinical trials. The prescription of standard
therapeutic regimens that are usually recommended for
patients with deep vein thrombosis of the lower limbs or
pulmonary embolism needs to be carefully assessed on an
individual basis, because the optimal timing of introduc-
tion, the optimal duration, and the dosages of anticoagulant
drugs may need to be adapted according to the clinical
presentation and to the presence of underlying disorders.
For example, in patients with CVT concomitant intrac-
erebral bleeding is frequently encountered and requires the
prolonged use of anticoagulants with a short half-life (UFH
or LMWH) until the clinical stability is achieved and the
neuro-radiological picture shows clear improvement.
Conversely, in patients with SVT presenting with con-
comitant gastrointestinal bleeding the use of any antico-
agulant can only be considered when the bleeding source is
treated and the patient is stable. Not uncommonly, SVT
patients do not receive anticoagulation because the risk of
bleeding is perceived to persistently outweight the risk of
recurrence. Table 2 provides a summary of therapeutic
interventions for VTE in unusual sites. CVT most com-
monly occurs in young females with gender specific risk
factors and has a favorable clinical history with a relatively
low long-term risk of recurrence. For this reason, indefinite
anticoagulation is only suggested for patients with recur-
rent disease or in the uncommon presence of permanent
risk factors. SVT is frequently associated with major per-
manent risk factors such as liver cirrhosis or cancer, which
place patients at a high long-term risk of recurrence. Thus,
for the majority of patients, with the exclusion of those
with SVT secondary to surgery or an acute infection,
indefinite treatment duration is suggested. RVO appears to
be a different disease entity caused by either local risk
factors or systemic cardiovascular risk factors. For this
reason, the need for anticoagulant therapy is extremely
uncertain and antiplatelet agents are frequently prescribed
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Table 3 Summary of guidance statements
Question Guidance statement
Cerebral vein thrombosis
(1) Should anticoagulant drugs in patients with CVT be considered? Anticoagulant drugs should be considered for all patients with CVT
(2) Is concomitant bleeding a contraindication to the use of
anticoagulant treatment?
Concomitant intracerebral bleeding at the time of CVT diagnosis
should not contraindicate the use of anticoagulant treatment.
Anticoagulants with a shorter half-life (UFH or LMWH) should be
administered over the first days of therapy and the introduction of
warfarin should be postponed until the patient is clinically stable and
the neuro-radiological picture improves
(3) Are low molecular weight heparin (LMWH) and unfractionated
heparin (UFH) similarly effective and safe for the acute phase
treatment?
LMWH and UFH appear to be similarly effective and safe for the acute
phase treatment. The use of LMWH may be preferred over UFH for
the majority of patients due to the practical advantages. The short
half-life of UFH may be preferred over LMWH for clinically
unstable patients or for patients requiring invasive procedures
(4) Is the standard treatment regimen used for patients with deep vein
thrombosis of the lower limbs (i.e. heparins for approximately
5–7 days and warfarin possibly started on the first treatment day)
applicable to all patients?
The introduction of warfarin should be considered when the patient is
clinically stable; that is, in the presence of normalized level of
consciousness or a remission of mental confusion, improvement in
headache and focal neurological deficits and improvement in the
neuro-radiological picture
(5) Is there a role for thrombolysis? The use of either systemic or local thrombolytic therapy should be
restricted to very selected high-risk patients only, such as in patients
who deteriorate despite adequate anticoagulant therapy in whom
other causes of deterioration have been ruled-out
(6) What is the optimal duration of anticoagulant therapy after a first
episode of CVT?
Anticoagulant treatment for a minimum of 3 months should be
considered in patients with transient risk factors. Patients without
known risk factors should be considered for 6–12 months of
anticoagulation. It appears safe to discontinue anticoagulant
treatment in the presence of transient risk factors such as oral
contraceptive use, while indefinite treatment duration should be
considered for patients with recurrent CVT and in patients with
permanent major risk factors including severe thrombophilia
(antithrombin, protein C or protein S deficiency; antiphospholipid
antibodies syndrome; homozygous factor V Leiden or prothrombin
gene mutation or combined heterozygous mutation)
(7) Is there a role for the direct oral anticoagulants? Given the absence of clinical experience with the use of the direct oral
anticoagulants in this setting, there is no evidence for or against their
use in clinical practice until additional data from clinical studies will
become available. If a decision to use these agents is made, their
use should be considered off-label and careful patient counselling
and clinical monitoring should follow. Ideally, patients receiving
direct oral anticoagulants should be included in prospective cohort
studies aimed to fill this knowledge gap
Splanchnic vein thrombosis
(1) Should all patients with SVT receive anticoagulant treatment? Anticoagulant treatment should be considered for all patients with
symptomatic SVT and no evidence of active bleeding. The decision
to administer anticoagulants to patients with incidentally detected,
asymptomatic SVT should be made on an individual basis, carefully
balancing the presence of risk factors for recurrence (e.g. underlying
prothrombotic conditions) and the risk of bleeding
(2) Is gastrointestinal bleeding at the time of diagnosis a
contraindication to anticoagulant therapy?
In the presence of active bleeding, anticoagulant treatment should be
initiated only when the bleeding source has been successfully treated
and the patient is clinically stable. The decision to start anticoagulant
treatment should be driven by the presence of major risk factors for
recurrence, the ability to address the underlying cause for bleeding,
and by the location and extent of thrombosis




(3) Is the standard treatment regimen used for patients with deep vein
thrombosis of the lower limbs (i.e. heparins for approximately
5–7 days and warfarin possibly started on the first treatment day)
applicable to all treatable patients?
This treatment regimen may not be appropriate for patients with
cancer-associated SVT or for patients with major risk factors for
bleeding (e.g. liver cirrhosis and/or known esophageal varices,
thrombocytopenia), for whom an initial course of treatment with
LMWH (3–6 months for cancer patients) is preferable. In patients
with thrombocytopenia, reduced doses of LMWH should be used
(prophylactic or half therapeutic dose) according to the platelet count
and to the concomitant presence of additional risk factors for
bleeding. For all other patients, the introduction of warfarin should be
considered only when the patient is clinically stable. In patients at
very high risk of bleeding or possibly requiring invasive procedures
the use of UFH may be preferred over LMWH
(4) What factors should be considered before starting anticoagulant
treatment in a patient with liver cirrhosis?
Routine endoscopic screening of esophageal varices and prophylactic
treatment of variceal bleeding should be considered for all cirrhotic
patients with SVT. In patients who are not actively bleeding,
anticoagulant treatment should be started as soon as possible with
initially reduced doses of LMWH (either prophylactic doses or half
therapeutic doses also according to the platelet count). Full doses of
LMWH should be started only after the completion of the banding
treatment
(5) Is there a role for thrombolysis? The use of thrombolytic agents should be limited to very selected
cases, such as patients with mesenteric vein thrombosis and with
signs of intestinal ischemia or patients whose conditions deteriorate
despite adequate anticoagulant therapy
(6) What is the optimal duration of anticoagulant therapy after a first
episode of SVT?
Anticoagulant treatment should be administered for a minimum of
3 months to all SVT patients. It appears safe to discontinue
anticoagulant treatment in the presence of major transient risk
factors, such as surgery or infections. For all other patients, including
patients with cirrhosis, cancer including myeloproliferative
neoplasms, or autoimmune disorders, indefinite treatment duration
should be considered with periodic careful assessment of the risks
and benefits
(7) Is there a role for the direct oral anticoagulants? Given the absence of clinical experience with the use of the direct oral
anticoagulants in this setting, there is no evidence for or against their
use in the management of patients with SVT. If a decision to use
these agents is made, their use should be considered off-label and
careful patient counselling and clinical monitoring should follow.
Ideally, patients receiving direct oral anticoagulants should be
included in prospective cohort studies aimed to fill this knowledge
gap
Retinal vein occlusion
(1) Should antithrombotic drugs in patients with newly diagnosed RVO
be considered?
There is no high-quality evidence to support routine use of
antithrombotic drugs for RVO patients. Neither the benefits nor the
risks of antithrombotic therapy have been well defined in this clinical
setting. That notwithstanding, antithrombotic treatment may be
considered in selected patients with recent onset of symptoms and no
local risk factors for thrombosis (e.g. glaucoma) or in patients with
underlying major prothrombotic risk factors such as the
antiphospholipid antibodies syndrome
(2) Which antithrombotic treatment should be preferred? If antithrombotic therapy is used, LMWH administered at therapeutic
doses may be considered for the acute phase treatment of RVO
(3) Is there a role for thrombolysis? The use of locally administered thrombolytic therapy should be limited
to very selected cases, such as RVO patients with total visual loss
(4) How long should antithrombotic drugs be administered in RVO
patients?
If antithrombotic therapy is used, LMWH should be administered for a
period of 1–3 months. Aspirin should be administered for an
indefinite period of time, when indicated
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in clinical practice, despite the lack of sufficient evidence
to support the role of any antithrombotic drug. Table 3
contains a summary of guidance statements for the man-
agement of VTE in unusual sites.
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